Xiaoyan Jiang

Xiaoyan Jiang, MD, PhD

Department of Medical Genetics
Distinguished Scientist, Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, BC Cancer, part of the Provincial Health Services Authority
Associate Member, Division of Hematology, Faculty of Medicine, University of British Columbia
Associate Member, Experimental Medicine, Faculty of Medicine, University of British Columbia
Associate Member, Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia
Adjunct Professor, Shanghai Institute of Medical Genetics, School of Medicine, Shanghai Jiaotong University
Professor
BC Cancer Research Centre

675 West 10th Avenue

Vancouver, BC V5Z 1L3

Canada
phone: 604–675–8141
fax: 604–877–0712
https://www.bccrc.ca/dept/tfl/people/xiaoyan-jiang

Research Interests:

The overall goal of my research program is to understand the molecular mechanisms and cellular functions of specific oncogenes, tumor suppressor genes, miRNAs/target genes, and their associated pathways/genetic networks, in the regulation of the properties of cancer/leukemic stem cells, signal transduction events, metabolism/mitochondria vulnerabilities, immune responses and initiation and progression of human leukemia and drug resistance. The ultimate objective is to identify and characterize key druggable molecules and pathways, using our well-established in vitro and patient-derived xenotransplantation (PDX) models, which will lead to new, rationally designed, more effective, and less toxic, personalized anti-cancer therapies. In particular, we are extremely interested in developing mechanism-based combination therapeutic strategies that can directly target drug-insensitive leukemic stem cells and mutated drug-resistant cells, to improve outcomes in leukemia patients, especially those destined to develop drug resistance. In collaboration with pharmaceutical companies, we have also been testing new therapeutic agents/inhibitors and combination treatment strategies that can effectively eradicate drug-resistant chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) stem/progenitor cells, by exploring novel oncolytic virotherapy, immunotherapy and nonviral gene therapy. These studies have led to several FDA-approved drugs for the treatment of leukemia patients.

Publications:

Google Scholar Profile

View publications on PubMed 

  1. Rothe K, Babaian A, Nakamichi N, Chen M, Chafe SC, Watanabe A, Forrest DL, Mager DL, Eaves CJ, Dedhar S, Jiang X.  Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors. Cell Stem Cell 27:110-124, 2020
  2. Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R, Zeng J, Ruschmann J, Petriv OI, O’Neill K, Maetzig T, Knapp DJHF, Nakamichi N, Brinkman R, Birol I, Forrest DL, Hansen C, Humphries K,  Eaves CJ, Jiang X. The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood Apr 8, 2020 (online ahead of print)
  3. Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, Forrest DL, Eaves CJ, Morin GB & Jiang X. PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia. Sci Transl Med 10: 427, 2018
  4. Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H,Jiang X, Weinstock DM, Graeber TG, Müschen M.  B-cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies. Cell 173:470-484.e18, 2018
  5. Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, Forrest DL, Humphries K & Jiang X. A novel BCR-ABL-AHI-1-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-induced autophagy. Leukemia 31: 2376-2387, 2017
  6. Huang Y, Su M, Jiang X (Corresponding Author), Zhou Y., Evidence of an oncogenic role of aberrant TOX activation in cutaneous T cell lymphoma. Blood 125:1435-1443, 2015
  7. Esmailzadeh S, Su MW, Zhou Y, Jiang X. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell Lymphoma. Leukemia 29: 1402-13, 2015
  8. Rothe K, Lin H , Lin K, Leung A, Wang HM, Malekesmaeili M, Brinkman RR, Forrest DL, Gorski S, Jiang X. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123: 3622-34, 2014
  9. Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgenson H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 105, 405-423, 2013
  10. Zeng F, Huang SZ, Gong ZJ, Chen MJ, Baldwin DA, Hu W, Qian H, Yan JB, Wang J, Xiao YP, Chalandon Y, Ringrose A, Ren ZR, Eaves A, Eaves C & Jiang X. Long-term deregulated human hematopoiesis in goats transplanted in utero with BCR-ABL-transduced lin–CD34+ cord blood cells. Cell Res. 23:859-862, 2013